The Inscripta® Blog
May 17, 2022
Aldevron Licenses the Manufacturing of MAD7™ Nuclease from Inscripta
A partnership between two CRISPR pioneers will provide the global scientific community with GMP and RUO MAD7 Nuclease
December 21, 2021
Inscripta’s MAD7™ CRISPR Nucleases Helping Hudson River Biosciences Improve Plant Editing
In a recent webinar, Ben Mijts of Inscripta, and Gabino Sanchez of Hudson River Biotechnology, demonstrate how Inscripta’s MADzyme™ family of…
November 16, 2021
Expanding the gene editing toolbox for Bacillus subtilis with the MAD7™ nuclease
A review article “The CRISPR toolbox for the gram-positive model bacterium Bacillus subtilis” published last month in Critical Reviews in…
August 24, 2021
In New Publications, Scientists Report Use of MAD7™ Nuclease for Plant Editing and More
A key part of Inscripta’s mission is making genome engineering more accessible. To that end, we released the MAD7™ nuclease sequence for…
July 27, 2021
Heterologous Protein Optimization with Inscripta’s Onyx Workflow
Optimization of protein function and expression is important for academic research as well as industrial applications. Historically,…
March 9, 2021
Scientists Deploy the MAD7™ Nuclease for Mammalian Genome Edits
Even before we launched our benchtop Onyx™ platform for automated genome engineering, the Inscripta team had already made progress in addressing…
December 15, 2020
University of Edinburgh Scientists Demonstrate Value of Open-Source MAD7™ Enzyme
Here at Inscripta, our vision for expanding access to digital genome engineering has always been broader than developing an automated benchtop…